Onward Medical Toekomstige groei

Future criteriumcontroles 2/6

Onward Medical's earnings are forecast to decline at 1.3% per annum while its annual revenue is expected to grow at 113.9% per year. EPS is expected to grow by 8.2% per annum.

Belangrijke informatie

-1.3%

Groei van de winst

8.2%

Groei van de winst per aandeel

Medical Equipment winstgroei	15.7%
Inkomstengroei	113.9%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	29 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BST:63E - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	39	-33	-34	-31	3
12/31/2025	10	-44	-38	-43	4
12/31/2024	2	-36	-34	-36	4
6/30/2024	0	-35	-29	-29	N/A
3/31/2024	0	-36	-31	-30	N/A
12/31/2023	1	-36	-33	-32	N/A
9/30/2023	1	-36	-33	-33	N/A
6/30/2023	2	-36	-33	-33	N/A
3/31/2023	2	-34	-30	-30	N/A
12/31/2022	2	-33	-27	-27	N/A
9/30/2022	2	-35	-27	-26	N/A
6/30/2022	2	-38	-27	-25	N/A
3/31/2022	2	-36	-25	-22	N/A
12/31/2021	1	-34	-22	-20	N/A
9/30/2021	1	-29	-18	-17	N/A
6/30/2021	1	-24	-14	-14	N/A
3/31/2021	1	-22	-13	-13	N/A
12/31/2020	1	-20	-13	-13	N/A
12/31/2019	1	-13	-10	-10	N/A
12/31/2018	0	-10	-7	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 63E is forecast to remain unprofitable over the next 3 years.

Winst versus markt: 63E is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: 63E is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: 63E's revenue (113.9% per year) is forecast to grow faster than the German market (5.5% per year).

Hoge groei-inkomsten: 63E's revenue (113.9% per year) is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if 63E's Return on Equity is forecast to be high in 3 years time

Onward Medical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Onward Medical N.V. has completed a Follow-on Equity Offering in the amount of €50 million.

Onward Medical N.V. has filed a Follow-on Equity Offering in the amount of €40 million.

Onward Medical N.V. Announces Board Changes

Onward® Medical Announces Third Implant of Brain-Computer Interface System to Restore Movement After Spinal Cord Injury

Onward Medical N.V., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

Onward Medical N.V. has filed a Follow-on Equity Offering in the amount of €20 million.

Onward Medical N.V. has filed a Follow-on Equity Offering in the amount of €20 million.

Onward Medical N.V. to Report Fiscal Year 2023 Results on Apr 25, 2024

Onward Medical N.V. Announces Nature Medicine Publication Highlights Potential for ONWARD ARC Therapy to Improve Mobility After Parkinson's Disease

Less than half of directors are independent

New minor risk - Market cap size

Onward Medical N.V. Announces First-in-Human Implant of ARC-IM™? Stimulator with Brain-Computer Interface (BCI) to Restore Arm, Hand, and Finger Function After Spinal Cord Injury

First half 2023 earnings released: €0.64 loss per share (vs €0.53 loss in 1H 2022)

Onward Medical N.V. Announces CFO Changes

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Onward Medical N.V. Announces First-In-Human Use of Arc-Im(Tm) Lead to Restore Movement and Function After Spinal Cord Injury

Full year 2022 earnings released

Less than half of directors are independent

Less than half of directors are independent

Onward Medical N.V. Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation After Spinal Cord Injury

Less than half of directors are independent

Onward Medical N.V. Announces Topline Results from the LIFT Home Study Supporting Safety and Feasibility of ARC-EX Therapy to Treat People with Spinal Cord Injury At Home

First half 2022 earnings released: EPS: €0 (vs €3.24 loss in 1H 2021)

ONWARD Medical N.V. Announces Appointment of Vivian Riefberg to Board of Directors

Onward Medical N.V. to Report First Half, 2022 Results on Sep 27, 2022

Less than half of directors are independent

Onward Reports Positive Topline Results from A Pivotal Study to Restore Arm and Hand Function in People with Spinal Cord Injury

Less than half of directors are independent

Onward Medical N.V. Announces Board Appointment

Onward Medical N.V., Annual General Meeting, Jun 10, 2022

Onward Medical N.V. Announces Completion of Enrollment in the Lift Home Study

Onward Medical N.V. Announces First Patient Enrollment in HemON Study and First-in-Human Use of its ARCIM Implantable Neurostimulator

Less than half of directors are independent

Onward Medical N.V. to Report Fiscal Year 2021 Results on Apr 26, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven